MDM2 Inhibitor and Immunotherapy Combination for Tumor Regression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, including immunotherapies and MDM2 inhibitors, have limitations in efficacy and durability of response, particularly in enhancing anti-tumor immune responses and overcoming resistance.
Innovation Solution
The combination of a MDM2 inhibitor, such as APG-115, with a modulator of an immune checkpoint molecule, enhances cancer treatment efficacy by synergistically activating immune responses and increasing the number of cytotoxic T cells within the tumor microenvironment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunotherapy alone is used to treat cancer, then anti-tumor immune response is activated, but response rates and durability of response are limited
Solution Approach 1:
The patent combines immunotherapy with MDM2 inhibitors to create a synergistic treatment approach. The combination merges the immune system activation capability of immunotherapy with the p53 pathway modulation of MDM2 inhibitors, resulting in enhanced anti-tumor immune responses and improved response rates compared to immunotherapy alone.
Solution Approach 2:
MDM2 inhibitors act as intermediaries that modulate the p53 pathway to enhance the effectiveness of immunotherapy. By inhibiting MDM2, the p53 pathway is activated, which in turn enhances the ability of immunotherapy to activate anti-tumor immune responses, thereby improving overall efficacy.
2Reliability
If MDM2 inhibitor alone is used to treat cancer, then p53 activity is enhanced, but anti-tumor immune response activation is limited
Solution Approach 1:
The patent merges MDM2 inhibitor therapy with immunotherapy to achieve both p53 activation and enhanced anti-tumor immune response. The combination allows the p53 pathway to be activated while simultaneously boosting immune system capability to target and eliminate tumor cells.
Solution Approach 2:
Immunotherapy acts as an intermediary that enhances the anti-tumor immune response activated by MDM2 inhibitors. While MDM2 inhibitors focus on p53 activation, the addition of immunotherapy provides the necessary immune system stimulation to achieve robust anti-tumor responses.
3Reliability
If combination therapy is used to enhance efficacy, then response rates and complete regression increase, but treatment complexity increases
Solution Approach 1:
The patent employs parameter changes in terms of dosing schedules and administration timing to manage the complexity of combination therapy. By optimizing the parameters of drug administration (dose, frequency, timing), the treatment achieves enhanced efficacy while maintaining manageable complexity through standardized protocols.
Data Source
AI summary
Disclosed herein are combination therapies comprising an effective amount of a modulator of the immune checkpoint molecule; and an effective amount of a MDM2 inhibitor.